INDEPENDENT THINKING. TRACEABLE EVIDENCE.Research edition · 29 October 2026
Modern DosingTHE PRACTITIONER’S PERSPECTIVEA clearer view of
the peptide economy ↗
The research library / Safety
Safety / SOURCE-DATED ANALYSIS

NAION: preserve the regulator’s uncertainty

MHRA updated semaglutide guidance about the very rare eye condition NAION and evidence of a potential association.

What changed

MHRA updated semaglutide guidance about the very rare eye condition NAION and evidence of a potential association.

What the evidence does not settle

UK communication. Potential association is not proof of causation in every visual event.

Evidence record

Event date: 2026-02-05. Source review: inherited source synthesis; not re-audited in this expansion. Editorial publication: 2026-10-29. Original source links below retain their publication dates. These dates are not interchangeable. This is targeted source synthesis, not an exhaustive archive or a qualified clinical/legal review.

  1. Original source ↗

Revision history

29 October 2026: migrated from the research edition, retaining source links and evidence qualifications; not re-audited in the current expansion. Report a proposed correction through Contact us; do not include patient data.

THE MODERN DOSING WEEKLY

The peptide news
that changes your week.

Evidence-backed developments. The moves that matter. What each means for your practice or business—in one weekly email.